OncoMatch/Clinical Trials/NCT06558981
Adjuvant Radiotherapy in High Risk Locally Advanced DTC
Is NCT06558981 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for thyroid cancer.
This study is a phase III randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer. Patients who meet the inclusion criteria were randomly assigned 1:1 to either the experimental group (adjuvant radiotherapy+RAI) or the control group (RAI), with LRFS as the primary endpoint of the study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Demographics
Prior therapy
Must have received: surgical total or near total thyroidectomy
Surgical total or near total thyroidectomy
Cannot have received: radiation therapy for the head and neck area
Previously received radiation therapy for the head and neck area
Cannot have received: radioiodine (131I)
Previously received 131I treatment
Cannot have received: targeted therapy
Previously received or currently receiving targeted therapy
Cannot have received: immunotherapy
Previously received or currently receiving immunotherapy
Cannot have received: chemotherapy
Previously received or currently receiving chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06558981 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy for the head and neck area, radioiodine, targeted therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 14 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify